Efdamrofusp alfa: an insight into the novel drug and its use in age-related macular degeneration
Efdamrofusp alfa shows promise as a novel treatment for nAMD, potentially offering improved efficacy over current anti-VEGF therapies. Nonetheless, further large-scale randomized clinical trials are essential to confirm its efficacy and safety in broader populations. The dual-inhibition strategy provides a new avenue for personalized AMD treatment, particularly for patients unresponsive to monotherapies.
Authors
- Amna Ibrahim
- Arghadip Das (ORCID: https://orcid.org/0000-0001-7617-7337)
- Sayed Mansoor Sediqi (ORCID: https://orcid.org/0000-0001-5105-6168)
- Niloufer Khan (ORCID: https://orcid.org/0000-0002-8631-5710)
- Arashdeep Singh (ORCID: https://orcid.org/0000-0001-6087-7240)
- Shahzad I. Mian (ORCID: https://orcid.org/0000-0002-5813-1527)
- Shree Rath (ORCID: https://orcid.org/0009-0000-4273-0827)
- Kashvi Panchal
Institutions
- Khyber Medical College (PK)
- Nil Ratan Sircar Medical College and Hospital (IN)
- Government Medical College, Amritsar (IN)
- University of Sharjah (AE)
- All India Institute of Medical Sciences Bhubaneswar (IN)
- American University of Afghanistan (AF)
- Smt. N.H.L. Municipal Medical College (IN)
- Medical College and Hospital, Kolkata (IN)
Publication Details
- Journal
- International Journal of Retina and Vitreous
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1186/s40942-025-00685-2
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00